GSK3A and myelodysplastic syndrome: Rigosertib can rescue Akt, ß-catenin, and GSK3a/ß signaling pathways commonly dysregulated in MDS cells (Figure 1) (Xu et al., 2014) but it is unclear if these effects hold true in vivo in patients with MDS treated with this drug (Stoddart et al., 2017).